A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Jul 26, 2007

Allotment of Stock Acquisition Rights(Stock Option Scheme as Stock-Linked Compensation Plan) (pdf 58KB)

Read more about Allotment of Stock Acquisition Rights(Stock Option Scheme as Stock-Linked Compensation Plan) (pdf 58KB)
Jul 3, 2007

Kyoto University and Astellas Co-research at the Innovation Center for Immunoregulation Technologies and Drugs of Next Generation (pdf 13KB)

Read more about Kyoto University and Astellas Co-research at the Innovation Center for Immunoregulation Technologies and Drugs of Next Generation (pdf 13KB)
Jun 26, 2007

Astellas Set Up The Nomination Committee and The Compensation Committee (pdf 24KB)

Read more about Astellas Set Up The Nomination Committee and The Compensation Committee (pdf 24KB)
Jun 18, 2007

Astellas Announces the Launch of Advagraf® in the UK and Germany (pdf 24KB)

Read more about Astellas Announces the Launch of Advagraf® in the UK and Germany (pdf 24KB)
Jun 11, 2007

Announcement of the Launch of the Selective COX-2 Inhibitor Celecox® Tablets in Japan (pdf 15KB)

Read more about Announcement of the Launch of the Selective COX-2 Inhibitor Celecox® Tablets in Japan (pdf 15KB)
May 15, 2007

Issuance of Stock Acquisition Rights for Stock Option Scheme as Stock-Linked Compensation Plan (pdf 28KB)

Read more about Issuance of Stock Acquisition Rights for Stock Option Scheme as Stock-Linked Compensation Plan (pdf 28KB)
May 15, 2007

Partial Amendments to the Articles of Incorporation (pdf 81KB)

Read more about Partial Amendments to the Articles of Incorporation (pdf 81KB)
May 7, 2007

Adverse Event of FG-2216 for the Treatment of Anemia (pdf 26KB)

Read more about Adverse Event of FG-2216 for the Treatment of Anemia (pdf 26KB)
May 1, 2007

Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Complicated Skin and Soft Tissue Infections in Europe (pdf 25KB)

Read more about Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Complicated Skin and Soft Tissue Infections in Europe (pdf 25KB)
Apr 27, 2007

Astellas Receives an European Commission Approval for Advagraf® (pdf 24KB)

Read more about Astellas Receives an European Commission Approval for Advagraf® (pdf 24KB)
Apr 26, 2007

Astellas Nominates a Director and Corporate Auditors (pdf 24KB)

Read more about Astellas Nominates a Director and Corporate Auditors (pdf 24KB)
Apr 26, 2007

Astellas Will Set Up The Nomination Committee and The Compensation Committee (pdf 24KB)

Read more about Astellas Will Set Up The Nomination Committee and The Compensation Committee (pdf 24KB)
Apr 2, 2007

Astellas Tokai Completed Merger with Two Group Companies (pdf 24KB)

Read more about Astellas Tokai Completed Merger with Two Group Companies (pdf 24KB)
Mar 30, 2007

ASTELLAS LICENSES REGENERON'S VELOCIMMUNE® TECHNOLOGY FOR DISCOVERING HUMAN MONOCLONAL ANTIBODIES (pdf 22KB)

Read more about ASTELLAS LICENSES REGENERON'S VELOCIMMUNE® TECHNOLOGY FOR DISCOVERING HUMAN MONOCLONAL ANTIBODIES (pdf 22KB)
Mar 26, 2007

Astellas Assigns All Outstanding Shares of Its Production Subsidiary to Choseido (pdf 24KB)

Read more about Astellas Assigns All Outstanding Shares of Its Production Subsidiary to Choseido (pdf 24KB)
Mar 26, 2007

Astellas Announces Cancellation of Treasury Stock (pdf 24KB)

Read more about Astellas Announces Cancellation of Treasury Stock (pdf 24KB)
Mar 20, 2007

Astellas Receives an FDA Action Letter for Prograf sNDA (pdf 27KB)

Read more about Astellas Receives an FDA Action Letter for Prograf sNDA (pdf 27KB)
Mar 2, 2007

FDA APPROVES ASTELLAS' VAPRISOL® FOR THE TREATMENT OF HYPERVOLEMIC HYPONATREMIA (pdf 59KB)

Read more about FDA APPROVES ASTELLAS' VAPRISOL® FOR THE TREATMENT OF HYPERVOLEMIC HYPONATREMIA (pdf 59KB)
Feb 28, 2007

Astellas Constructs New Buildings at its Miyukigaoka Research Center in Tsukuba (pdf 26KB)

Read more about Astellas Constructs New Buildings at its Miyukigaoka Research Center in Tsukuba (pdf 26KB)
Feb 26, 2007

Astellas Receives a Positive CHMP Opinion for EU Marketing Authorisation for FK506 Modified Release as a Once-Daily Immunosuppressant in Organ Transplantation (pdf 18KB)

Read more about Astellas Receives a Positive CHMP Opinion for EU Marketing Authorisation for FK506 Modified Release as a Once-Daily Immunosuppressant in Organ Transplantation (pdf 18KB)
Feb 23, 2007

ASTELLAS AND BOEHRINGER WON THE LAWSUIT AGAINST FLOMAX® GENERIC FOR PATENT INFRINGEMENT IN THE USA (pdf 23KB)

Read more about ASTELLAS AND BOEHRINGER WON THE LAWSUIT AGAINST FLOMAX® GENERIC FOR PATENT INFRINGEMENT IN THE USA (pdf 23KB)
Feb 13, 2007

Contents of Stock Acquisition Rights (Stock Option Scheme as Stock-Linked Compensation Plan) (pdf 23KB)

Read more about Contents of Stock Acquisition Rights (Stock Option Scheme as Stock-Linked Compensation Plan) (pdf 23KB)
Feb 1, 2007

Astellas Will Offer an Early Retirement Program to Japanese Employees (pdf 24KB)

Read more about Astellas Will Offer an Early Retirement Program to Japanese Employees (pdf 24KB)
Jan 29, 2007

Notice of Intention to Exercise Call Option on 1.25% Convertible Bonds due 2014 (pdf 23KB)

Read more about Notice of Intention to Exercise Call Option on 1.25% Convertible Bonds due 2014 (pdf 23KB)
Jan 26, 2007

Announcement of the Acquisition of Marketing Approval for the Selective COX-2 Inhibitor Celecox Tablet in Japan (pdf 12KB)

Read more about Announcement of the Acquisition of Marketing Approval for the Selective COX-2 Inhibitor Celecox Tablet in Japan (pdf 12KB)
Jan 26, 2007

Approval for Candin Antifungal Agent Funguard for Prophylaxis of Aspergillus and Candida infections in patients undergoing HSCT and Immunosuppressant Prograf for Lupus Nephritis in Japan (pdf 17KB)

Read more about Approval for Candin Antifungal Agent Funguard for Prophylaxis of Aspergillus and Candida infections in patients undergoing HSCT and Immunosuppressant Prograf for Lupus Nephritis in Japan (pdf 17KB)
Jan 26, 2007

Allotment of Stock Acquisition Rights(Stock Option Scheme as Stock-Linked Compensation Plan) (pdf 57KB)

Read more about Allotment of Stock Acquisition Rights(Stock Option Scheme as Stock-Linked Compensation Plan) (pdf 57KB)
Jan 26, 2007

Astellas and Pfizer Reached Settlement on Declaratory Judgment Action relating to Lipitor Agreement (pdf 12KB)

Read more about Astellas and Pfizer Reached Settlement on Declaratory Judgment Action relating to Lipitor Agreement (pdf 12KB)
Jan 24, 2007

Kirin and Astellas Enter Into a Licensing Agreement on an Immunosuppressive Fully Human Monoclonal Antibody (pdf 21KB)

Read more about Kirin and Astellas Enter Into a Licensing Agreement on an Immunosuppressive Fully Human Monoclonal Antibody (pdf 21KB)
Jan 23, 2007

Astellas Receives an Action Letter from FDA for NDA of FK506 MR in the U.S. (pdf 24KB)

Read more about Astellas Receives an Action Letter from FDA for NDA of FK506 MR in the U.S. (pdf 24KB)
Jan 11, 2007

Astellas Terminates Agreement on Acute Heart Failure Agent Carperitide (pdf 23KB)

Read more about Astellas Terminates Agreement on Acute Heart Failure Agent Carperitide (pdf 23KB)
Dec 26, 2006

ASTELLAS PHARMA US, INC. SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR ANTIFUNGAL PRODUCT MYCAMINE ® (pdf 38KB)

Read more about ASTELLAS PHARMA US, INC. SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR ANTIFUNGAL PRODUCT MYCAMINE ® (pdf 38KB)
Dec 21, 2006

Astellas Transfers Three European Plants to Temmler Group, Germany Pharmaceutical Company (pdf 24KB)

Read more about Astellas Transfers Three European Plants to Temmler Group, Germany Pharmaceutical Company (pdf 24KB)
Dec 20, 2006

Astellas Announces Dissolution of Astellas Insurance Service and Transfer of its Insurance Agency Business (pdf 30KB)

Read more about Astellas Announces Dissolution of Astellas Insurance Service and Transfer of its Insurance Agency Business (pdf 30KB)
Dec 20, 2006

Notice of Completion of Acquisition of the Company's Own Shares (pdf 23KB)

Read more about Notice of Completion of Acquisition of the Company's Own Shares (pdf 23KB)
Dec 13, 2006

Notice of the Result of Acquisition of the Company's Own Shares through ToSTNeT-2 (pdf 24KB)

Read more about Notice of the Result of Acquisition of the Company's Own Shares through ToSTNeT-2 (pdf 24KB)
Dec 12, 2006

Notice of Acquisition of the Company's Own Shares through ToSTNeT-2 (pdf 25KB)

Read more about Notice of Acquisition of the Company's Own Shares through ToSTNeT-2 (pdf 25KB)
Dec 6, 2006

Announcement of VISION 2015 (pdf 247KB)

Read more about Announcement of VISION 2015 (pdf 247KB)
Nov 30, 2006

SNDA FOR A FAST-ACTING POSTPRANDIAL HYPOGLYCEMIC AGENT FASTIC® TABLET / STARSIS® TABLET (pdf 10KB)

Read more about SNDA FOR A FAST-ACTING POSTPRANDIAL HYPOGLYCEMIC AGENT FASTIC® TABLET / STARSIS® TABLET (pdf 10KB)
Nov 7, 2006

Astellas Brought a Declaratory Judgment Action to Confirm the Initial Term of "Lipitor®" Agreement in Japan (pdf 27KB)

Read more about Astellas Brought a Declaratory Judgment Action to Confirm the Initial Term of "Lipitor®" Agreement in Japan (pdf 27KB)
Oct 26, 2006

Revision of the Interim Business Forecasts for FY2006 (pdf 29KB)

Read more about Revision of the Interim Business Forecasts for FY2006 (pdf 29KB)
Oct 23, 2006

Astellas, Toyo Pharmar, and Aska Pharmaceutical Compromised for Infringement of Patent on Harnal Capsule (pdf 74KB)

Read more about Astellas, Toyo Pharmar, and Aska Pharmaceutical Compromised for Infringement of Patent on Harnal Capsule (pdf 74KB)
Oct 4, 2006

Announcement of New Mid-Term Management Plan (pdf 88KB)

Read more about Announcement of New Mid-Term Management Plan (pdf 88KB)
Oct 4, 2006

Astellas Announces Acquisition of The Company's Own Shares (pdf 23KB)

Read more about Astellas Announces Acquisition of The Company's Own Shares (pdf 23KB)
Oct 4, 2006

Merger of Production Subsidiaries (pdf 26KB)

Read more about Merger of Production Subsidiaries (pdf 26KB)
Sep 21, 2006

Execution of Acquisition of the Company's Own Shares (pdf 15KB)

Read more about Execution of Acquisition of the Company's Own Shares (pdf 15KB)
Aug 21, 2006

DISCONTINUATION OF MARKETING ALLIANCE ON KETOLIDE ANTIBIOTICS, "KETEK TABLETS 300MG" (pdf 12KB)

Read more about DISCONTINUATION OF MARKETING ALLIANCE ON KETOLIDE ANTIBIOTICS, "KETEK TABLETS 300MG" (pdf 12KB)
Aug 1, 2006

Astellas Announces Acquisition of The Company's Own Shares (pdf 22KB)

Read more about Astellas Announces Acquisition of The Company's Own Shares (pdf 22KB)
Jul 18, 2006

Theravance and Astellas Add Japan to Collaboration on Telavancin, Investigational Antibiotic for Serious Infections (pdf 26KB)

Read more about Theravance and Astellas Add Japan to Collaboration on Telavancin, Investigational Antibiotic for Serious Infections (pdf 26KB)
Jul 18, 2006

Astellas Discontinues Development of Alzheimer's Disease Compound FK962 (pdf 14KB)

Read more about Astellas Discontinues Development of Alzheimer's Disease Compound FK962 (pdf 14KB)
Jul 10, 2006

Application Filed for the Osteoporosis Treatment ONO-5920/YM529 in Japan (pdf 64KB)

Read more about Application Filed for the Osteoporosis Treatment ONO-5920/YM529 in Japan (pdf 64KB)
Jul 3, 2006

Application for approval of additional indication for type 2 diabetic nephropathy for "Micardis" , Angiotensin II receptor blocker, is filed (pdf 300KB)

Read more about Application for approval of additional indication for type 2 diabetic nephropathy for "Micardis" , Angiotensin II receptor blocker, is filed (pdf 300KB)
Jun 30, 2006

Astellas Discontinues Development of Immunosuppressant FK778 (pdf 15KB)

Read more about Astellas Discontinues Development of Immunosuppressant FK778 (pdf 15KB)
Jun 1, 2006

Astellas Launches "Vesicare" for the treatment of Overactive Bladder in Japan (pdf 24KB)

Read more about Astellas Launches "Vesicare" for the treatment of Overactive Bladder in Japan (pdf 24KB)
May 31, 2006

Astellas to Support Relief Efforts following Big Earthquake in Indonesia (pdf 24KB)

Read more about Astellas to Support Relief Efforts following Big Earthquake in Indonesia (pdf 24KB)
May 30, 2006

Application for the immunosuppressant FK506 Modified Release Formulation in Japan (pdf 16KB)

Read more about Application for the immunosuppressant FK506 Modified Release Formulation in Japan (pdf 16KB)
May 30, 2006

Astellas Terminates Agreement on Anti-osteoporosis Agent FK481 (pdf 16KB)

Read more about Astellas Terminates Agreement on Anti-osteoporosis Agent FK481 (pdf 16KB)
May 15, 2006

Submission to the General Ordinary Meeting of Shareholders of Proposal concerning Remuneration, etc. for Directors (pdf 19KB)

Read more about Submission to the General Ordinary Meeting of Shareholders of Proposal concerning Remuneration, etc. for Directors (pdf 19KB)
May 15, 2006

Astellas Announces Cancellation of Treasury Stock (pdf 24KB)

Read more about Astellas Announces Cancellation of Treasury Stock (pdf 24KB)
May 15, 2006

Partial Amendments to the Articles of Incorporation (pdf 70KB)

Read more about Partial Amendments to the Articles of Incorporation (pdf 70KB)
Apr 28, 2006

Astellas Acquires the Rights to FG-2216 and FG-4592 for the Treatment of Anemia for Europe and Other Regions from FibroGen of the US

Japan, April 28 , 2006-Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) announced that Astellas and FibroGen, Inc. ("FibroGen" headquarters: South San...

Read more about Astellas Acquires the Rights to FG-2216 and FG-4592 for the Treatment of Anemia for Europe and Other Regions from FibroGen of the US
Apr 27, 2006

Ilypsa and Astellas Enter a Licensing Agreement on ILY101 for Treatment of Hyperphosphatemia in Japan (pdf 21KB)

Read more about Ilypsa and Astellas Enter a Licensing Agreement on ILY101 for Treatment of Hyperphosphatemia in Japan (pdf 21KB)
Apr 26, 2006

Astellas Announces Changes of President & CEO

Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) has today announced that Executive Vice President Masafumi Nogimori will be promoted to President and CEO...

Read more about Astellas Announces Changes of President & CEO
Apr 26, 2006

Astellas Nominates Outside Directors and an Outside Corporate Auditor to Strengthen Corporate Governance

Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) has today announced that in order to further strengthen corporate governance of Astellas, the Board of...

Read more about Astellas Nominates Outside Directors and an Outside Corporate Auditor to Strengthen Corporate Governance
Apr 26, 2006

Astellas Launches Vaprisol for the Treatment of Euvolemic Hyponatremia in Hospitalized Patients (pdf 57KB)

Read more about Astellas Launches Vaprisol for the Treatment of Euvolemic Hyponatremia in Hospitalized Patients (pdf 57KB)
Apr 24, 2006

Closure of Astellas CNS research in Edinburgh

- Expiration of the Joint Research Agreement with the University of Edinburgh -

Japan, April 24, 2006 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) has today announced that it decided not to continue its Astellas CNS research in...

Read more about Closure of Astellas CNS research in Edinburgh
Apr 21, 2006

Prograf Now Approved for Prophylaxis Use in Heart Transplantation across Europe

Tokyo, Japan and London, England, April 21 2006 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) today announced that the European Commission has...

Read more about Prograf Now Approved for Prophylaxis Use in Heart Transplantation across Europe
Apr 20, 2006

Announcement of the Acquisition of Marketing Approval for the Overactive Bladder Treatment Vesicare Tablet in Japan

Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) has obtained marketing approval for its overactive bladder treatment Vesicare (YM905) with the indication...

Read more about Announcement of the Acquisition of Marketing Approval for the Overactive Bladder Treatment Vesicare Tablet in Japan
Apr 20, 2006

Approval for Candin Antifungal Agent Funguard for Pediatrics in Japan

Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) has today announced that the candin antifungal agent, "Funguard® for Infusion" (generic name: micafungin...

Read more about Approval for Candin Antifungal Agent Funguard for Pediatrics in Japan
Apr 17, 2006

Consideration of the sale of Zepharma shares has been fixed

Tokyo, Japan April 17, 2006 - Astellas Pharma Inc. (President and CEO: Toichi Takenaka, "Astellas") today announced that the total consideration for the sale of all outstanding shares of Zepharma...

Read more about Consideration of the sale of Zepharma shares has been fixed
Apr 13, 2006

MAA Submission for Candin Antifungal Agent Micafungin in EU

Japan, April 13, 2006 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) has today announced that its EU subsidiary submitted a Marketing Authorization...

Read more about MAA Submission for Candin Antifungal Agent Micafungin in EU
Apr 3, 2006

Astellas Establishes New Subsidiary "Astellas Pharma Chemicals Co., Ltd."

Astellas Pharma Inc.("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) announced that Astellas today established a new active pharmaceutical ingredient (API) manufacturing...

Read more about Astellas Establishes New Subsidiary "Astellas Pharma Chemicals Co., Ltd."
Apr 3, 2006

Astellas to Acquire AMEVIVE (alefacept) (pdf 28KB)

Read more about Astellas to Acquire AMEVIVE (alefacept) (pdf 28KB)
Mar 31, 2006

Basic Licensing Agreement Signed on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811 (pdf 24KB)

Read more about Basic Licensing Agreement Signed on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811 (pdf 24KB)
Mar 31, 2006

Astellas Sells All Outstanding Shares of Its OTC Business Subsidiary, Zepharma Inc., to Daiichi Sankyo Co., Ltd. (pdf 13KB)

Read more about Astellas Sells All Outstanding Shares of Its OTC Business Subsidiary, Zepharma Inc., to Daiichi Sankyo Co., Ltd. (pdf 13KB)
Mar 31, 2006

Astellas Issues a Statement on Today's Nikkei News (pdf 8KB)

Read more about Astellas Issues a Statement on Today's Nikkei News (pdf 8KB)
Mar 31, 2006

Astellas Receives FDA Approval of Prograf (Tacrolimus) for Use in Heart Transplant Recipients (pdf 52KB)

Read more about Astellas Receives FDA Approval of Prograf (Tacrolimus) for Use in Heart Transplant Recipients (pdf 52KB)
Mar 23, 2006

Licensing Agreement for the Development, Manufacturing and Marketing of Anti-human Osteopontin Antibodies (pdf 10KB)

Read more about Licensing Agreement for the Development, Manufacturing and Marketing of Anti-human Osteopontin Antibodies (pdf 10KB)
Mar 9, 2006

Announcement of an Early Retirement Program Following the Transfer of Business Functions at Doshomachi Office

Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) has decided to offer an early retirement program for its employees at its Doshomachi office and employees...

Read more about Announcement of an Early Retirement Program Following the Transfer of Business Functions at Doshomachi Office
Mar 1, 2006

Dynogen Research Operation Acquired by Astellas Pharma Inc. (pdf 24KB)

Read more about Dynogen Research Operation Acquired by Astellas Pharma Inc. (pdf 24KB)
Feb 27, 2006

Astellas to Delist Shares from Three Stock Exchanges

Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) decided at a board meeting held today that it will apply for delisting of its common stocks from the...

Read more about Astellas to Delist Shares from Three Stock Exchanges
Feb 9, 2006

Astellas Issues a Statement on Today's Asahi News

Japan, February 9, 2006 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) today announced a following statement with regard to the news appeared on the...

Read more about Astellas Issues a Statement on Today's Asahi News
Jan 31, 2006

Recent Progress in the New Drug Development

Japan, January 31, 2006 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) today announced that it has recently achieved the following progress in its...

Read more about Recent Progress in the New Drug Development
Jan 31, 2006

Ferring and Astellas Enter a License Agreement on Degarelix for the Treatment of Prostate Cancer in Japan (pdf 22KB)

Read more about Ferring and Astellas Enter a License Agreement on Degarelix for the Treatment of Prostate Cancer in Japan (pdf 22KB)
Jan 27, 2006

SNDA for a Fast-Acting Postprandial Hypoglicemic Agent FASTIC Tablet / STARSIS Tablet for Combinaition Therapy with Biguanide was Filed (pdf 11KB)

Read more about SNDA for a Fast-Acting Postprandial Hypoglicemic Agent FASTIC Tablet / STARSIS Tablet for Combinaition Therapy with Biguanide was Filed (pdf 11KB)
Jan 27, 2006

Astellas Has Established Astellas Venture Management in the US

Japan, January 27, 2006 - Astellas Pharma Inc. (headquarters: Tokyo; president and CEO: Toichi Takenaka; hereafter "Astellas") today announced that it has established Astellas Venture Management...

Read more about Astellas Has Established Astellas Venture Management in the US
Jan 26, 2006

Letter of Intent Signed on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811 (pdf 23KB)

Read more about Letter of Intent Signed on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811 (pdf 23KB)
Dec 30, 2005

FDA Approves Astellas' VAPRISOL for the Treatment of Euvolemic Hyponatremia (pdf 74KB)

Read more about FDA Approves Astellas' VAPRISOL for the Treatment of Euvolemic Hyponatremia (pdf 74KB)
Dec 26, 2005

NDA for Immunosuppressant FK506 Modified Release Formulation Submitted in the US

Astellas Pharma US, Inc. (headquarters: Deerfield, Illinois; Chairman and CEO: Makoto Nishimura), a US subsidiary of Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO:...

Read more about NDA for Immunosuppressant FK506 Modified Release Formulation Submitted in the US
Dec 21, 2005

Study design and patient background of a large-scale clinical study, INNOVATION, of the angiotensin II receptor blocker MICARDIS was published in medical journal (pdf 2.7MB)

Read more about Study design and patient background of a large-scale clinical study, INNOVATION, of the angiotensin II receptor blocker MICARDIS was published in medical journal (pdf 2.7MB)
Dec 16, 2005

CO-Promotion Agreement between Astellas and sanofi-aventis Group Japan for Hypnotic Myslee (zolpidem tartrate) (pdf 11KB)

Read more about CO-Promotion Agreement between Astellas and sanofi-aventis Group Japan for Hypnotic Myslee (zolpidem tartrate) (pdf 11KB)
Dec 16, 2005

Astellas Transfers Its Group Member Company FMS Co., Ltd. to Canon System Solutions Inc. of the Canon Sales Group (pdf 11KB)

Read more about Astellas Transfers Its Group Member Company FMS Co., Ltd. to Canon System Solutions Inc. of the Canon Sales Group (pdf 11KB)
Dec 9, 2005

Purchase of the Company's Own Shares in the Market (pdf 8KB)

Read more about Purchase of the Company's Own Shares in the Market (pdf 8KB)
Nov 30, 2005

XenoPort and Astellas Enter a License Agreement on XP13512 in Japan and Five Asian Countries (pdf 36KB)

Read more about XenoPort and Astellas Enter a License Agreement on XP13512 in Japan and Five Asian Countries (pdf 36KB)
Nov 29, 2005

Astellas Sues Toyo Pharmar and Aska Pharmaceutical for Infringement of Patent on Harnal Capsule

Japan, November 29, 2005 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) today announced that Astellas filed a patent infringement lawsuit on November...

Read more about Astellas Sues Toyo Pharmar and Aska Pharmaceutical for Infringement of Patent on Harnal Capsule
Nov 7, 2005

Astellas Revises Its Dividends Forecasts for Current Fiscal Year (pdf 12KB)

Read more about Astellas Revises Its Dividends Forecasts for Current Fiscal Year (pdf 12KB)
Nov 7, 2005

Notice Regarding Acquisition of the Company's Own Shares (pdf 9KB)

Read more about Notice Regarding Acquisition of the Company's Own Shares (pdf 9KB)
Nov 7, 2005

Theravance and Astellas to Collaborate on Telavancin, Investigational Antibiotic for Serious Infections (pdf 25KB)

Read more about Theravance and Astellas to Collaborate on Telavancin, Investigational Antibiotic for Serious Infections (pdf 25KB)
Nov 2, 2005

Collaborative Search for Microorganisms in Vietnam (pdf 15KB)

Read more about Collaborative Search for Microorganisms in Vietnam (pdf 15KB)
Oct 28, 2005

Astellas Announces Dissolution of Astellas Systems (pdf 44KB)

Read more about Astellas Announces Dissolution of Astellas Systems (pdf 44KB)

Show per page

Discover more

Media contacts

Return to media homepage

Subscribe to news alerts

Choose Language

News